Literature DB >> 3774129

Chlorisondamine blocks acquisition of the conditioned taste aversion produced by (-)-nicotine.

C Reavill, I P Stolerman, R Kumar, H S Garcha.   

Abstract

Intraventricular microinjection (5 micrograms) of the bisquaternary ganglion-blocking drug chlorisondamine prevented acquisition of nicotine-induced conditioned taste aversion (CTA) in rats. This appeared to be a specific effect because chlorisondamine did not attenuate the conditioned taste aversion caused by apomorphine. These results support findings from other behavioural procedures indicating that centrally administered chlorisondamine causes a long-term blockade of central nicotinic mechanisms.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3774129     DOI： 10.1016/0028-3908(86)90204-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  11 in total

1.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.

Authors:  W A Corrigall; K B Franklin; K M Coen; P B Clarke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

3.  Non-nicotine constituents in e-cigarette aerosol extract attenuate nicotine's aversive effects in adolescent rats.

Authors:  Andrew C Harris; Peter Muelken; Yayi Swain; Mary Palumbo; Vipin Jain; Maciej L Goniewicz; Irina Stepanov; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2019-08-01       Impact factor: 4.492

4.  Effects of nicotine and chlorisondamine on cerebral glucose utilization in immobilized and freely-moving rats.

Authors:  T Marenco; S Bernstein; P Cumming; P B Clarke
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 5.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Nicotine cue in rats: effects of central administration of ganglion-blocking drugs.

Authors:  R Kumar; C Reavill; I P Stolerman
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

7.  Intraneuronal accumulation and persistence of radiolabel in rat brain following in vivo administration of [3H]-chlorisondamine.

Authors:  H el-Bizri; M G Rigdon; P B Clarke
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

8.  Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion.

Authors:  P B Clarke; I Chaudieu; H el-Bizri; P Boksa; M Quik; B A Esplin; R Capek
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

10.  Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered in vivo.

Authors:  H el-Bizri; P B Clarke
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.